ANASTROZOL SERVYCAL

ANASTROZOLE 1 mg

Coated Tablets

Each tablet of Anastrozol Servycal contains:
Anastrozole 1.00 mg
Lactose 47.00 mg
Microcrystalline cellulose 23.00 mg
Pregelatinized starch 20.00 mg
Sodium starch glycollate 3.00 mg
Povidone K-30 4.00 mg
Magnesium stearate 1.00 mg
Opadry II white 3.00 mg
Polyethylene glycol 6000 0.30 mg
Distilled water q.s. to 0.02 mL

THERAPEUTIC ACTIONS Antineoplastic, antiestrogen (potent and selective non-steroidal aromatase inhibitor).
ATC classification: L02BG.

INDICATIONS: anastrozole is indicated for adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.
The efficacy of this drug at early stages of cancer is based on an analysis of recurrence and disease-free survival in patients treated for a mean period of 31 months. Longer follow-up will be required to determine the efficacy of this drug in the long term.
Anastrozole is indicated as first-line therapy for postmenopausal women with hormone receptor positive or hormone receptor unknown locally advanced or metastatic breast cancer.
Anastrozole is also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression after tamoxifen treatment. Patients with estrogen receptors- negative (ER negative) breast cancer and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole.

PRESENTATIONS: Anastrozol Servycal is supplied in cartons containing 30 tablets.

Store in a dry place between 15º C and 30º C.